These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9322884)

  • 1. p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia.
    Guinn BA; Mills KI
    Leuk Lymphoma; 1997 Jul; 26(3-4):211-26. PubMed ID: 9322884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis.
    Guinn BA; Smith M; Padua RA; Burnett A; Mills K
    Leuk Res; 1995 Aug; 19(8):519-25. PubMed ID: 7658697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response.
    Behzad MM; Shahrabi S; Jaseb K; Bertacchini J; Ketabchi N; Saki N
    Biochem Genet; 2018 Jun; 56(3):149-175. PubMed ID: 29388070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation status of RASSF1A in patients with chronic myeloid leukemia.
    Avramouli A; Tsochas S; Mandala E; Katodritou E; Ioannou M; Ritis K; Speletas M
    Leuk Res; 2009 Aug; 33(8):1130-2. PubMed ID: 19193434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of progression in chronic myeloid leukemia by altering DNA methylation with a pyridoxine analogue.
    Sastry PS
    Med Hypotheses; 1999 Dec; 53(6):488-9. PubMed ID: 10687889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
    Amin HM; Hoshino K; Yang H; Lin Q; Lai R; Garcia-Manero G
    J Pathol; 2007 Aug; 212(4):402-10. PubMed ID: 17503411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
    Melo JV; Myint H; Galton DA; Goldman JM
    Leukemia; 1994 Jan; 8(1):208-11. PubMed ID: 8289491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation.
    Bi S; Barton CM; Lemoine NR; Cross NC; Goldman JM
    Exp Hematol; 1994 Jan; 22(1):95-9. PubMed ID: 8282066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
    Heller G; Topakian T; Altenberger C; Cerny-Reiterer S; Herndlhofer S; Ziegler B; Datlinger P; Byrgazov K; Bock C; Mannhalter C; Hörmann G; Sperr WR; Lion T; Zielinski CC; Valent P; Zöchbauer-Müller S
    Leukemia; 2016 Sep; 30(9):1861-8. PubMed ID: 27211271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New insight into DNA methylation in CML and its effect on clinical outcome--review].
    Tang Y; Hu JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1482-6. PubMed ID: 19099669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mutations of the p53 gene in hematologic neoplasms].
    Mori N; Mizoguchi H
    Nihon Rinsho; 1992 Jun; 50(6):1353-7. PubMed ID: 1518157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
    Stoklosa T; Poplawski T; Koptyra M; Nieborowska-Skorska M; Basak G; Slupianek A; Rayevskaya M; Seferynska I; Herrera L; Blasiak J; Skorski T
    Cancer Res; 2008 Apr; 68(8):2576-80. PubMed ID: 18413724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia.
    Güran S; Bahçe M; Beyan C; Korkmaz K; Yalçin A
    Haematologia (Budap); 1998; 29(3):181-93. PubMed ID: 10069444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.